Post-earnings recap
Reported
Mon, Mar 16, 2026
EPS actual
$-0.15
EPS est.
$-0.08
EPS surprise
-87.50%
1-day move
+44.23%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a loss per share of $0.15, which was significantly below expectations. Despite this miss, the stock surged by 44.23%, indicating that investors may be reacting positively to other aspects of the company's performance or future potential, even without detailed commentary from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | -87.50% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.